Why MAIA Biotechnology’s ateganosine program is entering a decisive lung cancer development phase
Find out how MAIA Biotechnology’s ateganosine trials could shape the next phase of lung cancer drug development today.
Pharma & Biotech
Pharma & Biotech
MAIA Biotechnology advances ateganosine cancer program with Phase 3 THIO-104 trial and 2026 catalyst timeline
Find out how MAIA Biotechnology is advancing ateganosine into Phase 3 and why its 2026 clinical milestones could reshape treatment options in lung cancer.